Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers. It develops KIN-2787, which is a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Diego, California.
IPO Year: 2020
Exchange: NASDAQ
Website: kinnate.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/17/2022 | $35.00 → $11.00 | Buy → Hold | Stifel |
| 7/28/2022 | $33.00 | Buy | H.C. Wainwright |
| 9/27/2021 | $46.00 | Buy | Jefferies |
| 9/23/2021 | $32.00 | Buy | Stifel |
| 7/13/2021 | Outperform | William Blair |
Stifel downgraded Kinnate BioPharma from Buy to Hold and set a new price target of $11.00 from $35.00 previously
H.C. Wainwright initiated coverage of Kinnate BioPharma with a rating of Buy and set a new price target of $33.00
Jefferies initiated coverage of Kinnate Biopharma with a rating of Buy and set a new price target of $46.00
Stifel initiated coverage of Kinnate Biopharma with a rating of Buy and set a new price target of $32.00
William Blair initiated coverage of Kinnate BioPharma with a rating of Outperform
Piper Sandler initiated coverage of Kinnate Biopharma with a rating of Overweight and set a new price target of $52.00